Clinical Trial Update: Hydroxychloroquine (HCQ) in Pediatric Interstitial Lung Disease (ILD) [Phase 2]

View source ↗

Summary

A Phase 2 study of hydroxychloroquine in children with interstitial lung disease was terminated, and the results have been posted (as of 2025-12-03).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Children Interstitial Lung Disease
• Diffuse Parenchymal Lung Disease
• Interstitial Lung Disease

Drugs mentioned

• Hydroxychloroquine (hydroxychloroquine)

Snippet

Sponsor: Matthias Griese | Conditions: Interstitial Lung Disease, Diffuse Parenchymal Lung Disease | Phase 2 | Status: TERMINATED | Results posted: 2025-12-03